Clinical Trial Update: A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the efficacy and safety of HS-10390 for primary IgA nephropathy; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• HS-10390

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Immunoglobulin a Nephropathy | Phase 2 | Status: NOT_YET_RECRUITING